公开(公告)号：US10941216B2

公开(公告)日：2021-03-09

申请号：US15593259

申请日：2017-05-11

Applicant: PFIZER INC. ,  RINAT NEUROSCIENCE CORP.

Inventor： Pavel Strop ,  Magdalena Grazyna Dorywalska ,  Arvind Rajpal ,  David Shelton ,  Shu-Hui Liu ,  Jaume Pons ,  Russell Dushin

IPC: A61K47/68 ,  C07K16/00 ,  C07K17/02 ,  A61P43/00 ,  C07K16/30

Abstract: The present invention provides engineered polypeptide conjugates (e.g., antibody-drug-conjugates, toxin-(biocompatible polymer) conjugates, antibody-(biocompatible polymer) conjugates, and bispecific antibodies) comprising acyl donor glutamine-containing tags and amine donor agents. In one aspect, the invention provides an engineered Fc-containing polypeptide conjugate comprising the formula (Fc-containing polypeptide)-T-A, wherein T is an acyl donor glutamine-containing tag engineered at a specific site or comprises an endogenous glutamine made reactive by the Fc-containing polypeptide engineering, wherein A is an amine donor agent, and wherein the amine donor agent is site-specifically conjugated to the acyl donor glutamine-containing tag or the endogenous glutamine. The invention also provides methods of making engineered polypeptide conjugates using transglutaminase.

公开(公告)号：US20170224816A1

公开(公告)日：2017-08-10

申请号：US15501752

申请日：2015-07-29

Applicant: RINAT NEUROSCIENCE CORP.

Inventor： Rachel Marie DeVay JACOBSON ,  Hong LIANG ,  David Shelton

IPC: A61K39/395 ,  A61K31/22 ,  A61K31/405 ,  A61K39/29 ,  A61K31/365

CPC classification number: A61K39/3955 ,  A61K31/22 ,  A61K31/365 ,  A61K31/405 ,  A61K39/292 ,  A61K2039/505 ,  A61K2300/00 ,  C07K16/40 ,  C07K2317/76

Abstract: The present invention relates to methods for the treatment of reducing LDL-cholesterol levels in a subject infected with hepatitis C virus (HCV) or at high risk of contracting HCV comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human PCSK9 protein. The subject treatment can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including hypercholesterolemia, dyslipidemia, hyperlipidemia, atherosclerosis, acute coronary syndrome and, more generally, cardiovascular disease (CVD).